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ABSTRACT 
Oral anticoagulation is pivotal in the management of thromboembolic risk in non-valvular atrial 
fibrillation (NVAF) patients. Effective anticoagulation is important to avoid major adverse events 
and medication adherence is central to achieve good anticoagulation control.  
Non-vitamin K antagonist oral anticoagulants (NOACs) are as effective and safe as vitamin K 
antagonist (VKAs) in NVAF patients. Due to the absence of routine anticoagulation monitoring 
with NOACs treatment, concerns have been raised about patient’s adherence to NOACs and real-
life data demonstrates variability in adherence and persistence. A multi-level approach, including 
patients’ preferences, factors determining physicians’ prescribing habits and healthcare system 
infrastructure and support, is warranted to improve initiation and adherence of anticoagulants. 
Adherence to NOACs is paramount to achieve a clinical benefit. Implementation of educational 
programs and easy-to-use tools to identify patients most likely to be non-adherent to NOACs, are 
central issues in improving the quality of NVAF anticoagulation management.  
 
Keywords: atrial fibrillation; oral anticoagulation; non-vitamin K antagonist oral anticoagulants; 
adherence; persistence.  
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INTRODUCTION 
Oral anticoagulant (OAC) therapy is recommended for the prevention of thromboembolic events 
in non-valvular atrial fibrillation (NVAF) patients(1). One of the major challenges for stroke 
prevention with OAC, vitamin K antagonists (VKAs) and non-VKA oral anticoagulants (NOACs), is 
medication adherence and persistence, to ensure efficacy and safety.   
 
Awareness of the importance of medication adherence as a pivotal issue in medical management 
has increased(2–4). The World Health Organisation (WHO) recommends that accurate assessment 
of medication adherence and strategies to counteract medication discontinuation are necessary 
for effective treatment in chronic diseases(5). Adherence implies that the patient chooses to 
appropriately follow prescriber’s recommendations concerning medication intake (6). Persistence 
with medication, defined as the time from initiation to discontinuation, should be pursued to 
increase the success of any prescription(7–9). Therefore, evaluation of the factors affecting 
medication adherence, specifically related to OAC for stroke prevention in NVAF patients, and 
development of strategies to improve it, are warranted but remain challenging(10).  
 
The aims of this review are: i) to discuss the relevant issues related to adherence and persistence 
for OAC therapy in the management of NVAF patients; ii) to summarise the available literature on 
adherence and persistence during treatment with NOACs in NVAF patients from both randomized 
clinical trials (RCTs) and observational studies; and iii) to review possible strategies to improve 
adherence and persistence with OAC therapy. 
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DETERMINANTS OF MEDICATION ADHERENCE FOR OAC IN NVAF PATIENTS: PATIENT 
PERSPECTIVES AND PHYSICIAN ADHERENCE TO GUIDELINES 
Achieving optimal prevention of stroke in NVAF patients is multifactorial, incorporating numerous 
patient, physician and healthcare system factors (Table 1).  It requires the availability of the 
medication, physicians to prescribe the most appropriate OAC drug to eligible patients and relies 
on patients taking their medications properly and continuously. Moreover, adequate 
infrastructure, resources and support from the local healthcare system are essential. These factors 
are often co-dependent and the determinants of medication adherence are complex and 
multifaceted [Figure 1].  
 
Since NOACs are as effective and safer than warfarin, their use in clinical practice is expected to 
improve patient uptake and clinicians' inclination to prescribe OAC therapy according to current 
guidelines(9). The more convenient fixed-dose regimen, fewer drugs interactions and no known 
food or alcohol interactions might improve patients’ uptake and adherence. Nevertheless, in a 
clinical setting where no laboratory monitoring of anticoagulation is required, poor medication 
adherence could be problematic(11). Due to scarcity of data about determinants of adherence to 
NOAC therapy, we will discuss factors related to non-adherence in relation to VKA therapy which 
may also be pertinent to NOACs, and where data is available, for NOACs. 
 
Suboptimal adherence to OAC is potentially harmful for NVAF patients due to the increased risk of 
stroke and bleeding. Poor medication adherence to VKA involves approximately one third of NVAF 
patients, based on observational studies and RCTs(12,13).  
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Patient and physician concerns about OAC therapy may be responsible for the substantial 
proportion of AF patients who discontinue OAC therapy within 1 year, with a resulting increased 
embolic stroke risk(14). 
 
The Patient’s Perspective 
Increasingly AF guidelines highlight the importance of discussing patients’ preferences for 
treatment as an integral part of the decision-making process when prescribing OAC therapy(15–
18), as patients’ experiences of AF, their patients’ values and preferences  are likely to affect OAC 
uptake and adherence(15,16,19).  
 
Real-world studies reveal that 1-year discontinuation rates for warfarin-naïve patients initiating 
VKAs are consistently high (26% -35%)(7,20,21). Moreover, between 40–50% of NVAF patients do 
not even start VKA therapy, often due to the fear of fatal complications(20). 
Data from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) 
which assessed patterns of warfarin discontinuation over 1 year of follow-up found that the 
majority were classified as patient-related(14). 
 
Demographics, Patients’ Understanding and Behavioural Factors 
Non-adherence to VKAs appears more prevalent among younger patients, those of lower social-
economic status, and those less well-informed about their disease and medications(20–22). 
Attitudinal and behavioural patient-related factors also play a role in medication non-adherence. 
Thus, depressive symptoms or pessimistic attitude towards the future, psychiatric illness, impaired 
quality of life due to co-morbidities, lack of social support, alcohol and drug abuse, were also 
commonly reported reasons for non-adherence to VKAs(23–26). In addition, the perception of 
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taking too many pills, that taking OAC increases bleeding, as well as worries about worsening 
health outcomes all contribute to low VKA adherence(27), (28). Moreover, evidence indicates that 
medication adherence in chronic diseases is time-dependent and decreases consistently after the 
first 3 months of treatment(3). 
One US survey showed that women were significantly less willing to switch from warfarin to a 
NOAC than men, while older patients were significantly more willing to switch to a NOAC than 
younger patients(29). Another US survey of Veterans from primary care and OAC clinics, found 
that most patients would prefer to actively participate in OAC decision-making(30). Qualitative 
research has shown that physicians tend to believe that shared decision-making occurs regularly 
when choosing OAC, while patients believe that the physician often chooses the medication for 
them(31,32). 
 
Recently, a European survey(33) demonstrated that: i) most AF patients were aware of the need 
for OAC for stroke prevention; ii) patients were not concerned about renal function checks and 
around 20% of NOAC-treated patients ignored these checks; iii) OAC discontinuation was 
approximately 14.5% but around half of the patients did not know the reason for NOAC cessation 
and iv) discontinuation related to bleeding was evident in only 4%. Overall, these findings suggest 
the need to address the lack of knowledge and awareness of AF patients towards requirements 
and benefits of NOACs prescription. 
 
Comorbidities and Concomitant Medications 
Co-morbidities also play an important role in non-adherence. For example, severe cognitive 
impairment affects patients’ knowledge of medications and ability to adhere(34). Moreover, the 
patient’s comorbidity burden may indirectly influence medication adherence due to the increasing 
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complexity associated with a wide range of medications(35). The presence of polypharmacy, 
defined as the prescription of 5 or more drugs at the same time for several different conditions, 
has been suggested to influence adherence to treatments(36). Of note, polypharmacy was found 
to be highly prevalent among AF patients(37,38) and was associated with worst clinical 
outcomes(37,38).  
 
The Physician’s Perspective 
Physicians’ perspectives on OAC also have to be considered when accounting for non-optimal 
treatment. Specifically, physicians’ often overestimate bleeding risk and this is the most commonly 
cited explanation for under-prescription of OACs(39). Indeed, data from the ORBIT AF registry 
reported that the most common reason for discontinuation was physician preference (47.7%), 
followed by patient refusal/preference (21.1%), then bleeding events (20.2%)(14). 
 
Knowledge in Balancing Thromboembolic and Bleeding Risk 
Prescription of OAC may be influenced by the presence of potential contraindications. The most 
frequently listed contraindications include prior bleed, high bleeding risk, patient 
refusal/preference, and frequent falls/frailty(40,41), although none is an absolute 
contraindication.  
 
Recent systematic reviews emphasize the impact of physicians’ apprehension about feeling 
responsible for a major bleed, which seemed to outweigh their concern about risk of 
stroke(41,42). Physicians were less likely to prescribe VKAs after a patient experienced a major 
bleed associated with OAC. Conversely the occurrence of an ischaemic stroke in an untreated AF 
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patient did not influence the odds that a physician would prescribe warfarin in subsequent 
patients(42). 
 
Recent data from the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) Pilot 
General Registry showed that up to 40% of AF patients were sub-optimally anticoagulated(43) 
Clinical factors associated with physicians’ non-adherence to guidelines were the presence of 
concomitant coronary artery disease, which predicted both under- and over-treatment. Persistent 
AF and symptomatic status also predicted over-treatment(43) whilst smoking, concomitant 
malignancy and previous pharmacological cardioversion were significantly associated with under-
treatment. Both under-treatment and overtreatment were associated with worst clinical 
outcomes.(43) 
 
Physicians’ Concerns over Patient Adherence to NOACs 
Many physicians have the perception that even minor deviations from strict adherence can 
significantly decrease the efficacy of NOACs, due to their shorter half-lives, and this may 
significantly affect the NOAC prescription rate(44). One study,(45) found that although the 
majority of physicians prescribed NOACs and considered NOACs to be equally safe or safer than 
VKAs, the proportion of patients receiving NOACs was relatively low (mostly <10%). Physician’s 
perceived that adherence to VKAs and NOACs was similar, but 10.6% stated that they felt patient 
adherence was better with VKAs(45). 
 
A European survey revealed that considerable time and resources are dedicated in daily clinical 
practice to inform AF patients about their risk profile and available OAC therapies(46). 
Communication of stroke and bleeding risk communication was given highest priority for 
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discussion with patients. Overall the strongest driver for AF patients choosing a NOAC over a VKA 
were the fixed dosing, without the need for routine laboratory monitoring of the anticoagulation 
effect. In the majority of centres, the proportion of patients who would refuse NOAC despite being 
informed about the benefits and risks of therapy was <10%; main reasons for NOAC refusal were 
patients' fear of bleeding with NOAC and under-appreciation of stroke risk despite adequate 
information(46). 
 
Healthcare Systems and Settings 
Systematic reviews suggest that specialized management by OAC clinics is associated with better 
anticoagulation control compared to community-based services(47,48). In addition, data from a 
large observational study demonstrated that hospitalization is associated with a significantly 
higher rate of both critically sub- and supra-optimal international normalized ratios (INR)(49).  
 
Further, reimbursement could influence the OAC prescription. A recent analysis of AF patients 
with high thromboembolic risk from the US PINNACLE registry, found that insurance type granting 
greater prescription coverage substantially increased the use of both OAC and NOACs.(50). 
 
ADHERENCE AND PERSISTENCE TO NOACs 
Absence of INR monitoring and lifestyle restrictions with NOACs could potentially improve 
adherence, although from a pharmacokinetic standpoint, it is likely that non-adherence to NOACs 
will be less well tolerated than with VKAs. The long average half-life of warfarin ensures some 
residual anticoagulant effect up to 72 hours following ingestion of the last tablet. If AF patients 
report an occasional missed dose, due to the slow-offset of VKA, they might be at less risk of 
thromboembolic complications compared with NOACs users. However, an analysis from the UK 
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General Practice Research Database reported that persistence with VKA progressively decreased 
during a 5-year follow-up. One-year persistence was 70% among chronic AF patients, falling to 
50% at 2 years and 35% at 5 years. Currently we have relatively limited data on NOAC adherence.   
 
NOACs Persistence in Phase III Randomized Clinical Trials 
Evaluation of adherence in patients treated with NOACs is challenging(10). The Phase III NOAC 
RCTs only reported discontinuation rates, rather than adherence per se; discontinuation rates 
ranged from 18% to 35% across studies (see Figure 2)(51–55). Of note, the occurrence of a serious 
adverse event was only a minor determinant of non-persistence (Figure 2).  Nevertheless, data on 
discontinuation rates and persistence with NOACs seen in these RCTs cannot be translated 
automatically into clinical practice, since RCTs are likely to enhance adherence by frequent follow-
up visits and pill-count procedures, in selected and highly motivated patients.   
 
From Clinical Trials to Real-Life Observations in NOACs Use 
Data on NOAC adherence from actual clinical practice are needed to provide a more reliable 
estimate of medication adherence and persistence rates(56–59). 
 
Adherence and persistence rates to NOACs in observational studies vary dramatically, from 
38.0%(60) to 99.7%%(61) (Table 2). In most studies adherence is defined as the proportion of 
patients with a proportion of days covered (PDC) (i.e. numbers of days on which medication was 
taken as prescribed) of ≥80%, while persistence refers to the percentage of patients who do not 
discontinue therapy. To date 22 studies have investigated adherence and/or persistence to 
NOACs. 
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Dabigatran 
Six studies exploring adherence and persistence to dabigatran alone have been published so 
far(8,61–65). A small study reported high adherence (99.7%)(61), meanwhile a recent analysis 
from the Veterans Health Administration reported dabigatran adherence up to 74%, with huge 
variations related to site-level practices(62). The proportion of adherent patients was higher at 
sites performing appropriate selection, patients’ education/monitoring and with specific 
pharmacist-based activities(62). More recently, an analysis of prescription reported an adherence 
of 75% during the first year.(63) Patients at high risk for stroke and patients with great co-
morbidities showed better adherence. Similarly, data from another large administrative database 
found that lower thromboembolic risk and higher bleeding risk were the main factors associated 
with dabigatran discontinuation(8). Despite this, dabigatran users still reported higher persistence 
than patients treated with warfarin (63.3% vs. 38.8%)(8).  
 
Similar data overall data about adherence and persistence for dabigatran have also been reported 
by Tsai et al(65). Interestingly, the authors reported that warfarin-naïve patients had consistently 
lower adherence and persistence rates compared to warfarin-experienced patients (both p<0.001) 
(Table 2)(65). 
Consistently, a subgroup analysis, derived from the Dresden NOAC registry, reported a 
discontinuation rate of 36.4% for dabigatran with an overall incidence of 25.8 per 100 patient-
years. Incidence rate for discontinuation was found to be higher in the first 6 months of treatment 
(46.6 per 100 patient-years)(64). The largest proportion of discontinuation was for non-bleeding 
side effects (32.3%) and due to physician choice (13.7%); this mirrors data from the RCTs. Only 
8.9% patients discontinued NOAC due to adverse bleeding events(64). 
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Rivaroxaban 
In US healthcare claims database of propensity-matched cohorts of AF patients newly initiated on 
rivaroxaban or warfarin, patients treated with rivaroxaban had significantly higher persistence 
rates compared to warfarin-treated patients(66,67). Results from the Dresden NOAC registry(68) 
reported a discontinuation rate of 13.6 per 100 patient-years.  The most common reasons for 
discontinuation were bleeding complications (30%)(68). A further analysis of this registry reported 
high levels of adherence both at 360 (85% of patients) and 720 days (78.8%)(69). One large 
international multicentre study about rivaroxaban use in real-life reported that 20.1% 
discontinued rivaroxaban after 1-year follow-up, mainly due to adverse events(70). 
 
Apixaban 
Adherence to apixaban in NVAF patients has been investigated in an RCT; the “AEGEAN” study 
(ClinicalTrials.Gov unique identifier: NCT01884350). Patients started on apixaban were randomized 
to receive ‘usual care’ or ‘usual care plus additional education’. Adherence (88.5% vs. 88.3%) and 
persistence (90.5% vs. 91.1%) rates were not significantly different between the two groups after 
6-months of treatment(71). The final results are still awaited. 
 
Comparison of ≥1 NOAC 
A recent meta-analysis demonstrated that NOAC discontinuation rates were not statistically 
different when compared to warfarin and aspirin for prevention of stroke in NVAF patients(72). 
Studies that have examined adherence to ≥1 NOAC report varying and inconsistent results. A 
population derived from a well-structured AF clinic showed that patients treated with apixaban 
had the lowest incidence of discontinuation after 367 median follow-up time compared to both 
dabigatran (11.5 vs. 30.0 per 100 patient-years, p<0.001) and rivaroxaban (11.5 vs. 23.9 per 100 
  13 
patient-years, p=0.001)(73). Similar data were reported by an observational study from a Japanese 
anticoagulation clinic(74). 
A retrospective analysis of a US healthcare claims database was performed to evaluate NOACs 
adherence(75). Significantly more patients were adherent to rivaroxaban (72.7%) than either 
dabigatran (67.2%) or apixaban (69.5%)(75). 
 
Recently a flurry of studies reporting adherence and/or persistence data for NOAC versus VKAs 
have been published (Table 2)(60,76–80). A large prospective cohort reported that the unadjusted 
persistence in dabigatran users was lower when compared to rivaroxaban, apixaban and 
warfarin(76). Initiation with both warfarin and apixaban were associated with a better persistence 
at 1-year follow-up. Higher adherence rates were reported for rivaroxaban compared to 
dabigatran treatment (p<0.001), while no difference was found when compared to apixaban(76).  
 
Evidence from a UK primary care database reported significantly higher persistence rates with all 
NOACs at both 180 and 365 days compared to VKA treatment (both p<0.0001)(77). Similar data 
were reported from a retrospective US insurance database, showing an overall higher adherence 
for NOACs when compared to warfarin (p<0.001).  Another study reported overall adherence to 
NOACs (dabigatran, rivaroxaban, apixaban) of >70%.(80). 
 
Another large “real-world” observational study found that patients with rivaroxaban where 
consistently more persistent and adherent both at 180 days and 360 days when compared to 
dabigatran and VKAs(78). Similar evidence was reported by US claim database, showing that 
adherence to rivaroxaban was consistently higher than dabigatran(60). Similarly, in the study by 
Alberts et al.(80), patients treated with once daily rivaroxaban were found to be more adherent 
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than those treated with twice daily NOACs (dabigatran and apixaban) (73.1% vs. 67.9% 
respectively, p<0.001). 
 
Practical Considerations about NOACs Adherence and Persistence 
All NOACs are rapidly absorbed and have half-lives below 24 hours; nevertheless, different dosing 
regimens have been selected, depending on the drug. Modelling analyses that combine patients’ 
dosing history data and pharmacokinetic properties of the drugs, have demonstrated that a twice-
daily dosing regimen maintains a better continuity of drug plasma levels than once-daily dosing for 
drugs with a half-life of 12 h(81).  
 
Nevertheless, it is unknown whether any NOAC regimen is superior in guaranteeing the best net 
clinical benefit in terms of thromboembolic prevention efficacy and safety. In modelling data, a 
larger decrease in anticoagulant activity was computed with a single dose omitted from an OD 
regimen compared with a single or more pills omitted from a BID regimen(81). As the clinical 
relevance of anticoagulant activity fluctuations has not yet been clinically elucidated, it is essential 
to ensure that drugs are taken according to the prescribed regimen to obtain results resembling 
those seen in the RCTs(82). 
 
The current perception is that peak plasma drug-concentrations are important determinants of 
bleeding, especially since a twice-daily regimen reduces peak plasma drug concentrations 
compared with once daily dosing, and this should, in theory, maximize safety. However, 
pharmacokinetic analyses from a Phase II study on edoxaban in AF patients reported less bleeding 
events with OD regimen rather than BID dosing, albeit with the same daily dose(83). 
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STRATEGIES TO IMPROVE PATIENT’S ADHERENCE TO ORAL ANTICOAGULATION 
Identification of factors accounting for non-adherence to VKAs and NOACs in clinical subgroups is 
essential for targeting patient management and improving overall adherence to medication. The 
evaluation of the time in therapeutic range (TTR) represents one of the most reliable ways to 
evaluate treatment efficacy in patients undertaking VKA-based anticoagulant therapy(84). In fact, 
TTR inversely related to both thromboembolic and bleeding events in patients treated with VKAs 
(85–87). The ESC Working Group on Thrombosis recommends achieving a TTR of at least 70%(88). 
 
A simple clinical-based tool to identify patients who may be less likely to achieve and maintain 
good anticoagulation control has been proposed in the setting of NVAF, the SAMe-TT2R2 score (Sex 
(female), Age (<60 years), Medical history, Treatment (VKA interacting drugs, i.e. amiodarone), 
Tobacco use, Race (non-Caucasian))(89). The SAMe-TT2R2 score has been validated in several 
cohorts (90–93) and could be used to aid OAC decision-making(94). 
Those patients with a SAMe-TT2R2 score>2 (hence with a high probability of ineffective 
anticoagulation), could be targeted with intensive educational strategies to improve patients’ 
knowledge and awareness about AF and anticoagulant treatment, in order to achieve a better 
adherence(15). Indeed, the "TREAT" study showed that warfarin-treated AF patients, who 
received a one-off educational group session, achieved better anticoagulant control, assessed by 
TTR, compared to patients treated with usual care(95). Similar strategies, tailored to each NOAC 
and considering social, ethnic and cultural/geographical differences(5), could be developed to 
improve adherence to NOACs and consequently reduce adverse events.  
 
Regular scheduled contact with healthcare professionals may improve adherence with NOACs. The 
European Heart Rhythm Association practical guide to NOACs provides a framework for structured 
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start-up and follow-up of patients receiving NOACs(96). Regular review of patient adherence by 
health care providers (HCPs) along with a patient card recording all relevant information, may be 
needed to improve patients’ adherence(96). An active multidisciplinary approach involving 
professional HCPs such as nurses, general practitioners (GPs) and cardiologists has been also 
proposed(97).  
 
An European Working Group convened to consider the challenges facing HCPs and healthcare 
systems in different countries and the educational gaps that hinder optimal patient 
management(82).  
 
Education needs and responsibilities have been identified and should be implemented in clinical 
practice(82). Updates on available evidence on NOACs should be provided with role-appropriate 
levels of complexity to all HCPs. Simple flow charts, as well as software and e-support, should be 
made available for guiding treatment. HCPs should be responsible for reinforcement of key 
educational messages about the anticoagulant they are taking, assessment of patient 
understanding, periodic contact to follow-up and active interactions among all HCPs(82). 
 
The long-term management of patients receiving anticoagulation could be efficiently handled by 
centralised anticoagulation clinics. As an alternative, GPs or specialist nurses could also take 
responsibility. The initial prescriber (or a member of his team) should  be responsible for initial 
patient education and for educating and up-skilling other HCPs about NOACs(82). 
 
Awareness of the importance of OAC for stroke prevention and practical information on the 
medication (when and how to take it, what dose etc.) through education seems to be a reliable 
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strategy to try to improve patient’s adherence. This goal could be achieved through 
interdisciplinary AF-expert programs for management of AF patients(81,98,99).  In this context, 
the central role of nurses in anticoagulation management is emerging(99,100).  Nurse-led 
programmes have been shown to allow more systematic care and co-ordinated follow-up(98,101). 
Therefore, when compared to usual care, an integrated chronic care program including a nurse-
led, guideline-based, software-supported AF clinic resulted in a significant reduction in the number 
of cardiovascular deaths or hospitalizations over one-year follow-up(99). Moreover, a nurse-based 
AF approach was tested in the SAFETY trial, finding a significant increase in the number of days 
being alive and free of hospital admissions, compared to hospital follow-ups(101). 
 
Among HCPs, pharmacists may also play an important role in the monitoring patient adherence to 
NOACs(82).  Pharmacists’ daily practice is an ideal forum for checking that patients understand the 
dose and regimen and are adherent, as well as reinforcing general educational messages (82). 
  
Finally, patients taking NOACs must be made aware of their condition and treatment. Information 
should be provided using appropriate language, in a variety of formats (verbally, booklets, apps, 
websites etc.), and confirmation of patients’ understanding should be checked. It is important to 
utilise each patient visit to discuss the modalities of intake (once-daily vs. twice-daily; interactions 
with food and other medications), the importance of strict adherence to the prescribed dosing 
regimen to reduce the likelihood of serious adverse events and to convince patients that NOACs 
therapy should not be discontinued. With the gradual availability of antidotes to NOACs, it is even 
more important that the patient knows what drug they are taking, as the administration of the 
‘wrong’ antidote in an acute bleeding event may have catastrophic consequences. 
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What else can we do? To improve medication adherence HCPs should assess (through discussion 
and pill counts) and record adherence; re-educate patients on the importance of the strict intake 
schedule; inform patients about adherence aids (medication boxes, smartphone applications, 
timers, etc.)(96).  In a recent review, electronic monitoring (EM) feedback was the biggest 
adherence-influencing factor(102). Of the currently EM options, automatic compilation of dosing 
histories using electronic detection of package entry (smart packages) or direct detection of pills in 
the stomach (smart pills) seem to be promising reliable and sufficiently richly sampled methods to 
estimate patients’ adherence(81).  
 
CONCLUSIONS  
In the context of NVAF patients’ management, patient-, physician-, and healthcare-system factors 
have a significant impact on adherence to the prescribed anticoagulation regimen.  
Although several  papers about adherence and/or persistence with NOACs treatment in AF 
patients exist, the  heterogeneity of setting, definition of adherence employed and results 
suggests that more robust research is needed to elucidate which of the  available NOACs is 
associated with adherence and persistence, in combination with a reduction in major adverse 
events. 
A multi-level approach, including patients’ preferences for treatment and physicians’ prescription 
determinants, as well as structured multidisciplinary healthcare systems, are warranted to 
improve uptake and adherence to anticoagulant therapy.  This is particularly important in the era 
of greater use of NOACs where medication adherence would be paramount to avoid and/or 
reduce adverse events. Identification of simple practical tools to detect patients at risk of non-
adherence, as well as implementation of patients and physician educational programs and 
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strategies to improve adherence, are central issues to be addressed in future studies for improving 
the quality of anticoagulation management in NVAF patients.   
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FIGURE LEGENDS 
 
Figure 1: Medication Adherence Main Determinants 
Figure 2: Discontinuation Rates in Phase III NOACs trials 
Legend: NOACs= non-vitamin K antagonist oral anticoagulants; SAE= serious adverse event; *data 
related only to bleeding episodes.  
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Table 1: Factors Influencing Medication Adherence in Chronic Disease 
 MAIN CATEGORIES EXAMPLES 
PATIENT 1. Demographics 
 
 
 
 
Age 
Ethnicity 
Educational Level 
Socioeconomic Status 
Presence of Caregivers 
2. Patient-Related Medical Conditions 
 
Co-morbidities 
Disability 
Fragility 
Cognitive Impairment 
Tolerance and Side effects of Drugs 
Polypharmacy 
3. Behavioural Factors 
 
Social Isolation 
Psychiatric Disorders 
4. Patient Understanding of the 
Medication Regimen 
Awareness of the risk and benefit related to 
drug assumption and discontinuation 
PHYSICIAN/HEALTH 
SYSTEM 
1. Knowledge Adherence to Guidelines 
Awareness of Recommendations and Risk 
Treatment 
2. Work Setting Specialized Centres 
Structures of Health Care System 
Continuity in Patients-Doctor Relation 
Multidisciplinary approach 
3. Cost of the Care Accessibility (Public vs. Private Services) 
Economic Concerns 
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Table 2: Adherence and Persistence Rates in Real-Life Studies on N
O
ACs Use 
Study 
Year 
Country 
N
O
AC 
Design 
N
 
Adherence/Persistence 
Prim
ary 
O
utcom
es 
Follow
-U
p 
Dabigatran 
 
 
 
 
 
 
 
 
Schulm
an(61) 
2013 
Canada 
Dabigatran 
O
bservational Prospective 
139 
99.7%
 
Adherence Rate 
3 m
onths 
Zalesak(8) 
2013 
U
nited States 
Dabigatran 
O
bservational Retrospective 
3,370 
63.3%
 
Persistence Rate 
1 year 
Tsai(65) 
2013 
U
nited States 
Dabigatran 
O
bservational Retrospective 
17,691 
56.5%
# / 62.6%
^ 
67.4%
# / 71.2%
^ 
Adherence &
 
Persistence Rate 
6 m
onths 
Gorst-Rasm
ussen(63) 
2015 
Denm
ark 
Dabigatran 
O
bservational Retrospective 
2,960 
76.8%
 
Adherence Rate 
1 year 
Shore(62) 
2015 
U
nited States 
Dabigatran 
O
bservational Retrospective 
4,863 
74%
 
Adherence Rate 
30 days 
Rivaroxaban 
 
 
 
 
 
 
 
 
Laliberté(66) 
2014 
Canada 
Rivaroxaban 
O
bservational Retrospective 
3,654 
82.5%
 
M
ajor bleeding, 
ICH, GI bleeding, 
stroke/SE, VTE 
6 m
onths 
N
elson(67) 
2014 
U
nited States 
Rivaroxaban 
O
bservational Retrospective 
7,259 
77.1%
 
Persistence Rate 
184 days 
Beyer-W
estendorf(68) 
2015 
Germ
any 
Rivaroxaban 
O
bservational Retrospective 
1,204 
81.5%
 
Persistence Rate 
544 days 
Cam
m
(70) 
2015 
European 
M
ultinational 
Rivaroxaban 
O
bservational Prospective 
6,784 
79.8%
 
M
ajor Bleeding, 
All-cause Death, 
All AEs and SAEs 
1 year 
Hecker(69) 
2016 
Germ
any 
Rivaroxaban 
O
bservational Prospective 
1,204 
78.8%
 
Stroke/TIA/SE 
ISTH M
ajor 
Bleeding 
796.2 days 
(m
ean) 
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Legend: AE= adverse event; GI= gastrointestinal; ICH= intracranial haem
orrhage; N
O
AC= N
on-vitam
in K antagonist oral anticoagulant; SAE= 
serious adverse event; SE= system
ic em
bolism
; TIA= transient ischem
ic attack; VTE= venous throm
boem
bolic event; *Dabigatran, Rivaroxaban, 
Apixaban; #w
arfarin naïve; ^w
arfarin experienced. 
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Table 2 (continued): Adherence and Persistence Rates in Real-Life Studies on N
O
ACs U
se 
Study 
Year 
Country 
N
O
AC 
Design 
N
 
Adherence/Persistence 
Prim
ary 
O
utcom
es 
Follow
-U
p 
M
ultiple N
O
ACs 
 
 
 
 
 
 
 
 
Forslund(76) 
2015 
Sw
eden 
Dabigatran 
Rivaroxaban 
Apixaban 
O
bservational Prospective 
2,701 
2,074 
1,352 
92.0%
 / 74.4%
 
95.7%
 / 77.4%
 
93.5%
 / 85.9%
  
Adherence &
 
Persistence Rate 
1 year 
M
artinez(77) 
2015 
U
K 
All N
O
ACs* 
O
bservational Retrospective 
914 
79.2%
 
Persistence Rate 
1 year 
M
cHorney(75) 
2015 
U
nited States 
Dabigatran 
Rivaroxaban 
Apixaban 
O
bservational Retrospective 
6,548 
11,095 
3,532 
67.2%
 
72.7%
 
69.5%
 
Adherence Rate 
1 year 
Shiga(74) 
2015 
Japan 
All N
O
ACs* 
O
bservational Retrospective 
401 
70.0%
 
Discontinuation 
Rate 
12 m
onths 
Alberts(80) 
2016 
U
nited States 
All N
O
ACs* 
O
bservational Retrospective 
38,868 
70.3%
 
Ischem
ic Stroke 
12 m
onths 
Beyer-W
estendorf(78) 
2016 
Germ
any 
Dabigatran 
Rivaroxaban 
O
bservational Retrospective 
821 
1,317 
47.6%
 / 47.3%
 
62.6%
 / 53.1%
 
Adherence &
 
Persistence Rate 
360 days 
Colem
an(60) 
2016 
U
S 
Dabigatran 
Rivaroxaban 
O
bservational Retrospective 
10,878 
10,878 
38.0%
 
49.0%
 
Adherence Rate 
24 m
onths 
Yao(79) 
2016 
U
S 
Dabigatran 
Rivaroxaban 
Apixaban 
O
bservational Retrospective 
10,235 
12,336 
3,900 
38.5%
 
50.5%
 
61.9%
 
Stroke/TIA/SEE 
M
ajor Bleeding 
1.1 years 
(m
edian) 
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Legend: AE= adverse event; GI= gastrointestinal; ICH= intracranial haem
orrhage; N
O
AC= N
on-vitam
in K antagonist oral anticoagulant; SAE= 
serious adverse event; SE= system
ic em
bolism
; TIA= transient ischem
ic attack; VTE= venous throm
boem
bolic event; *Dabigatran, Rivaroxaban, 
Apixaban; #w
arfarin naïve; ^w
arfarin experienced. 
 


